Jinlong Wang, Mengjuan Shi, Lili Huang, Qing Li, Shanshan Meng, Jingyuan Xu, Ming Xue, Jianfeng Xie, Songqiao Liu, Yingzi Huang
PURPOSE: Terlipressin improves renal function in patients with septic shock. However, the mechanism remains unclear. Here, we aimed to evaluate the effects of terlipressin on renal perfusion in patients with septic shock.
MATERIALS AND METHODS: This pilot study enrolled patients with septic shock in the intensive care unit of the tertiary hospital from September 2019 to May 2020. We randomly assigned patients to terlipressin and usual care groups using a 1:1 ratio. Terlipressin was intravenously pumped at a rate of 1.3 μg/kg/hour for 24 h. We monitored renal perfusion using renal contrast-enhanced ultrasound (CEUS). The primary outcome was peak sonographic signal intensity (a renal perfusion parameter monitored by CEUS) at 24 h after enrollment.
RESULTS: 22 patients were enrolled in this study with 10 in the terlipressin group and 12 in the usual care group. The baseline characteristics of patients between the two groups were comparable. The peak sonographic signal intensity at 24 h after enrollment in the terlipressin group (60.5 ± 8.6 dB) was significantly higher than that in the usual care group (52.4 ± 7.0 dB; mean difference, 7.1 dB; 95% CI, 0.4-13.9; adjusted = .04). Patients in the terlipressin group had a lower time to peak, heart rates, norepinephrine dose, and a higher stroke volume at 24 h after enrollment. No significant difference in the urine output within 24 h and incidence of acute kidney injury within 28 days was found between the two groups.
CONCLUSIONS: Terlipressin improves renal perfusion, increases stroke volume, and decreases norepinephrine dose and heart rates in patients with septic shock.
World J Gastroenterol. 2012 Oct 7;18(37):5225-30
[PMID:
23066317]
Intensive Care Med. 2004 Apr;30(4):597-604
[PMID:
14673520]
Crit Care. 2013 Feb 04;17(1):204
[PMID:
23394211]
Intensive Care Med. 2019 May;45(5):730-732
[PMID:
30725132]
Crit Care Med. 2020 Mar;48(3):e209-e218
[PMID:
31804299]
Eur J Gastroenterol Hepatol. 2010 Sep;22(9):1085-92
[PMID:
20453655]
Crit Care. 2015;19 Suppl 3:S8
[PMID:
26729241]
Intensive Care Med. 2011 Jun;37(6):963-9
[PMID:
21336777]
Intensive Care Med. 2018 Nov;44(11):1816-1825
[PMID:
29971593]
Intensive Care Med. 2010 Jan;36(1):83-91
[PMID:
19841897]
Intensive Care Med. 2017 Mar;43(3):304-377
[PMID:
28101605]
Ann Intensive Care. 2020 Jan 22;10(1):9
[PMID:
31970567]
JAMA. 2005 Aug 17;294(7):813-8
[PMID:
16106006]
J Surg Res. 2014 May 15;188(2):503-9
[PMID:
24582066]
Circulation. 1997 Mar 4;95(5):1122-5
[PMID:
9054839]
Curr Opin Crit Care. 2020 Dec;26(6):543-548
[PMID:
33074946]
J Intensive Care. 2019 Mar 12;7:16
[PMID:
30923620]
BMJ. 2019 Jan 9;364:k4891
[PMID:
30626586]
JAMA. 2016 Feb 23;315(8):801-10
[PMID:
26903338]
J Intensive Care. 2020 Oct 31;8(1):83
[PMID:
33292658]
Crit Care. 2018 Jun 15;22(1):161
[PMID:
29907130]
Hepatobiliary Pancreat Dis Int. 2012 Aug 15;11(4):434-7
[PMID:
22893473]
J Vasc Res. 1995 Mar-Apr;32(2):100-5
[PMID:
7734655]
Am J Physiol. 1989 Feb;256(2 Pt 2):F274-8
[PMID:
2916660]
Front Pharmacol. 2019 Dec 23;10:1492
[PMID:
31920672]
JAMA. 2016 Feb 23;315(8):775-87
[PMID:
26903336]
J Surg Res. 2015 May 15;195(2):568-79
[PMID:
25769491]
Lancet. 2020 Jan 18;395(10219):200-211
[PMID:
31954465]
Crit Care. 2009;13(4):R130
[PMID:
19664253]
N Engl J Med. 2021 Mar 4;384(9):818-828
[PMID:
33657294]
J Surg Res. 2016 Jan;200(1):274-82
[PMID:
26253455]
JAMA. 2016 Aug 2;316(5):509-18
[PMID:
27483065]
Nephrol Dial Transplant. 2012 Feb;27(2):674-81
[PMID:
21690200]
Hypertens Res. 2002 Jan;25(1):77-83
[PMID:
11924730]
Crit Care. 2013 Jul 12;17(4):R138
[PMID:
23849270]